FSD Pharma Reports Positive Phase 1 Results for FSD201
Ticker: QNTM · Form: 6-K · Filed: Mar 5, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, pharmaceutical, drug-development
TL;DR
FSD Pharma's FSD201 is safe in humans, moving closer to treating inflammation.
AI Summary
FSD Pharma Inc. filed a Form 6-K on March 5, 2024, to report positive results from its Phase 1 clinical trial for FSD201 (ultramicronized PEA). The trial, conducted in healthy volunteers, demonstrated FSD201's safety and tolerability, with no serious adverse events reported. The company is advancing its development of FSD201 for various inflammatory conditions.
Why It Matters
Positive Phase 1 results suggest FSD201 is safe and well-tolerated, paving the way for further clinical development in treating inflammatory diseases.
Risk Assessment
Risk Level: medium — The company is still in the early stages of clinical development, and future trials may not yield positive results.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- FSD201 (drug) — Compound being tested
- Nathan Coyle (person) — Chief Financial Officer
- March 5, 2024 (date) — Filing date
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing is to report positive results from a Phase 1 clinical trial for FSD Pharma's drug candidate, FSD201.
What was the outcome of the Phase 1 clinical trial for FSD201?
The Phase 1 trial in healthy volunteers demonstrated that FSD201 is safe and well-tolerated, with no serious adverse events reported.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
Nathan Coyle, Chief Financial Officer, signed the Form 6-K.
What is the SIC code for FSD Pharma Inc.?
The Standard Industrial Classification (SIC) code for FSD Pharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the next step for FSD201 based on these results?
The company is advancing the development of FSD201 for various inflammatory conditions, implying further clinical trials are planned.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-03-05 08:02:05
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 16KB
- fsd_ex991img5.jpg (GRAPHIC) — 7KB
- 0001654954-24-002589.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: March 5, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3